Minaris Viral Vectors provides integrated CDMO services to help advance in vivo and ex vivo viral vector programs from plasmid and vector design through process development, GMP manufacturing, testing, release, and fill-finish. Based in Philadelphia, our Viral Vectors Center of Excellence supports LVV and AAV programs with transient, packaging, and producer cell-line approaches, plasmid engineering, cell banking, analytical development, tech transfer, and scalable suspension manufacturing up to 1000L. With 80+ GMP viral vector batches delivered across ex vivo and in vivo programs, Minaris combines proven GMP execution, co-located testing, vector-specific quality systems, and differentiated OXGENE™ technologies, including TESSA®, XOFLX®, plasmid solutions, and a clonal HEK293 cell line with DMF, to help improve yield, quality, scalability, and COGs while reducing handoffs and de-risking scale-up.
Download the flyer to learn how Minaris Viral Vectors can support your program with integrated development, manufacturing, testing, release, and technology solutions designed to accelerate the path from construct to clinical supply.
